A PYMNTS Company

EU: Commission clears $66 billion Actavis deal

By  |  March 16, 2015

Actavis and Allergan have cleared the last hurdle antitrust hurdle closing their $66 billion merger agreement.

The European Commission has signed off on the tie-up, the companies said Monday. And with that, they expect the acquisition to wrap up Tuesday, they said in a statement.

While the drugmakers haven’t until now had all of their official OK’s to tie the knot, the integration process has been underway for awhile. Actavis quickly started rebranding the company as a “growth pharma”–to set it apart from the slow-growth Big Pharma companies it will join in the industry’s global top 10 when the deal closes.

 

Full Content: The Wall Street Journal

 

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.